Vyndaqel
Europe approves first treatment for transthyretin amyloidosis in cardiomyopathy patients: Pfizer’s Vyndaqel
February 19, 2020Research and Development, Sales and Marketing Europe, Pfizer, Vyndaqel, pharma, transthyretin amyloidosis
The European Commission (EC) has awarded marketing approval to Pfizer’s Vyndaqel (tafamidis), it has emerged, for the treatment of wild-type …
Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients
December 16, 2019Sales and Marketing Pfizer, Vyndaqel, pharma
Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …
FDA approves first two drugs for transthyretin amyloid cardiomyopathy
May 7, 2019Manufacturing and Production, Sales and Marketing FDA, Pfizer, US, Vyndamax, Vyndaqel, pharma
The FDA has approved its first two therapies for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), …
Latest content
Boyds expands Regulatory Affairs team to support growing demand
October 16, 2026
Sterling doubles ADC manufacturing capacity at Welsh facility
October 16, 2026
Femtosecond laser cuts lung tumour margin assessment time
October 15, 2026
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
October 15, 2026
